Podcasts - Page 2

Our podcast, “Not So Different,” provides insights from and discussions with stakeholders from across the biosimilars landscape.
The recent weeks and months have seen a number of policy proposals from the Trump administration that impact community oncologists. On this week's podcast, Laura Joszt, associate editorial director of The Center for Biosimilars®, caught up with Ted Okon, MBA, executive director of the Community Oncology Alliance.
Last year, biosimilar developer Pfizer submitted a citizen petition to the FDA in which it called on the agency to issue guidance clarifying how drug sponsors can communicate about biosimilars. After the petition was filed, The Center for Biosimilars® invited an expert group of stakeholders to discuss misinformation about biosimilars as well as what steps are necessary to root out and address the misinformation.
In January of last year, several hospital groups, representing approximately 450 US hospitals, revealed plans to form a nonprofit generic drug company in a bold move designed to address generic drug shortages and high prices affecting their hospitals.
Those who follow the biosimilars space closely are aware that, in the context of the US market, legal concerns regarding biosimilars can be just as regulatory ones in informing how drug makers do business. One recent case that impacts on upon the biosimilars market was recently heard before the before the United States Supreme Court, and the outcome of the case will potentially impact drug makers seek patent protection for various aspects of their products.
Recently, a new systematic review evaluating US and European provider awareness of biosimilars found a persistent lack of education on both sides of the Atlantic. This week, The Center for Biosimilars® is speaking with Sonia T. Oskouei, PharmD, one of the authors of the review, about the findings.
Last year was a banner year for biosimilars, both in the United States and abroad. In this episode of the podcast, Laura Joszt, associate editorial director of The American Journal of Managed Care®, the parent publication of The Center for Biosimilars®, interviews senior editor, Kelly Davio, about the key developments in biosimilars last year.
Welcome to Season 2 of Not So Different, a podcast from The Center for Biosimilars®

Recently, Louis Tharp, the cofounder and executive director of the patient advocacy organization the Global Healthy Living Foundation, visited our studios in New Jersey to talk about how high drug costs impact patients with rheumatic diseases, and how biosimilars can be part of the solution. Our podcast this week features a portion of our discussion about biologics, biosimilars, and the patient’s viewpoint.
This week on “Not So Different,” our guest is Ali McBride, PharmD, MS, BCPS. McBride is pharmacist who serves as the Clinical Coordinator for Hematology and Oncology at The University of Arizona Cancer Center. He’s also the lead author of a recent study that showed that using biosimilar filgrastim can expand patients’ access to treatment with obinutuzumab.
This week on the podcast, we’re pleased to welcome our guest, Leigh Purvis, MPA. Purvis is the director of health services research at AARP’s public policy institute. Her work focuses on a variety of prescription drug and mental health-related issue, with an emphasis on prescription drug pricing, biologic drugs, and prescription drug coverage under Medicare. 

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.